Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington, shared an article he and his colleagues authored on X:
“We just published TROPiCS04 P3 trial data
Annals of Oncology with Tom Powles, Y. Loriot, Scott Tagawa et al.
Primary OS endpoint was not met, higher ORR with SG (23%) vs taxane/vinflunine (14%), G-CSF primary prophy only ~20% ->G5 neutropenic events on SG.”
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
Authors: Tom Powles et al.
